The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance
Agostina Nardone(Baylor College of Medicine), Rachel Schiff(Baylor College of Medicine)
Cited by 65
Related Papers
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545
Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers - role of estrogen receptor and HER2 reactivation
|Breast Cancer Research|2011|283
Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Xenografts With Multiagent HER-Targeted Therapy
|JNCI Journal of the National Cancer Institute|2007|189
β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib
|Breast Cancer Research|2011|162